GENERIC NAME: linagliptin BRAND NAME: Tradjenta DRUG CLASS: antidiabetic PHARMACODYNAMICS: Tradjenta (linagliptin) is an orally-active inhibitor of the

dipeptidyl peptidase-4 (DPP-4) enzyme. DPP-4 degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucosedependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation. DOSAGE: Linagliptin may be taken with or without food. The recommended dose is 5 mg once daily. INDICATIONS: Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus CONTRAINDICATIONS: Hypersensitivity, Type 1 diabetes mellitus, Diabetic ketoacidosis ADVERSE EFFECTS: The most common side effects of linagliptin are stuffy or runny nose and sore throat. Hypoglycemia may occur when linagliptin is combined with insulin or a sulfonylurea-type drug. Allergic reactions and muscle pain also may occur. Pancreatitis also has been reported. NURSING RESPONSIBILITIES: -Before taking linagliptin, assess if the client have allergy in medication.-Before using this medication, tell your doctor or pharmacist your medical history, especially of: disease of the pancreas(pancreatitis). -You may experience blurred vision, dizziness, or drowsiness due to extremely low or high blood sugar levels. Do not drive, use machinery, or do any activity that requires alertness or clear vision until you are sure you can perform such activities.